Short- and long-term effect of simvastatin therapy on the heterogeneity of cardiac repolarization in diabetic patients

Pharmacological Research

Volumn 57, Issue 5, 2008, Pages 393-397

  Tekin, Abdullah ^a   Tekin, Göknur ^a   Sezgin, Alpay Turan ^a   Müderrisoǧlu, Haldun ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Arrhythmia; Diabetes mellitus; QT dispersion; Statin; Sudden cardiac death

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; SIMVASTATIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART REPOLARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT DISPERSION; SINGLE BLIND PROCEDURE;

ADULT; ARRHYTHMIAS, CARDIAC; CARDIAC ELECTROPHYSIOLOGY; CASE-CONTROL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HEART RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SIMVASTATIN; TIME FACTORS;

EID: 44549087784     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2008.04.001     Document Type: Article

References (39)

1. Ford E.S., and DeStefano F. Risk factors for mortality from all causes and from coronary heart disease among persons with diabetes. Am J Epidemiol 133 (1991) 1220-1230
2. Curb J.D., Rodriguez B.L., Burchfiel C.M., Abbott R.D., Chiu D., and Yano K. Sudden death, impaired glucose tolerance, and diabetes in Japanese American men. Circulation 91 (1995) 2591-2595
3. Olshausen K.V., Witt T., Pop T., Treese N., Bethge K.P., and Meyer J. Sudden cardiac death while wearing a Holter monitor. Am J Cardiol 67 (1991) 381-386
4. Kuo C., Munakata K., Reddy P., and Surawicz B. Characteristic and possible mechanism of ventricular arrhythmia dependent on the dispersion of action potential durations. Circulation 67 (1983) 1356-1367
5. Zabel M., Portnoy S., and Franz M.R. Electrocardiographic indexes of dispersion of ventricular repolarization: an isolated heart validation study. J Am Coll Cardiol 25 (1995) 746-752
6. Naas A.A.O., Davidson N.C., Thompson C., Cummings F., Ogston S.A., Jung R.T., et al. QT and QTc dispersion are accurate predictors of cardiac death in newly diagnosed non-insulin-dependent diabetics: cohort study. Br Med J 316 (1998) 745-746
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
8. Tamargo J., Caballero R., Gómez R., Núñez L., Vaquero M., and Delpón E. Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. Pharmacol Ther 114 (2007) 107-126
9. Kostapanos M.S., Liberopoulos E.N., Goudevenos J.A., Mikhailidis D.P., and Elisaf M.S. Do statins have an antiarrhythmic activity?. Cardiovasc Res 75 (2007) 10-20
10. Day C.P., McComb J.M., and Campbell R.W.F. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J 63 (1990) 342-344
11. Cowan J.C., Hilton C.J., and Griffiths C.J. Sequence of epicardial repolarization and configuration of the T wave. Br Heart J 60 (1988) 424-433
12. Sylven J.C., Horacek B.M., Spencer C.A., Klassen G.A., and Montague T.J. QT interval variability on the body surface. J Electrocardiol 17 (1994) 179-188
13. Kautzner J., and Malik M. QT interval dispersion and its clinical utility. PACE 20 (1997) 2625-2640
14. Sawicki P.T., Kiwitt S., Bender R., and Berger M. The value of QT interval dispersion for identification of total mortality risk in non-insulin-dependent diabetes mellitus. J Intern Med 243 (1998) 49-56
15. Cardoso C.R.L., Salles G.F., and Deccache W. Prognostic value of QT interval parameters in type 2 diabetes mellitus. Results of a long-term follow-up prospective study. J Diabetes Complications 17 (2003) 169-178
16. Cardoso C., Salles G., Bloch K., Deccache W., and Siqueira-Filho A.G. Clinical determinants of increased QT dispersion in patients with diabetes mellitus. Int J Cardiol 79 (2001) 253-262
17. Arildsen H., May O., Christiansen E.H., and Damsgaard E.M. Increased QT dispersion in patients with insulin-dependent diabetes mellitus. Int J Cardiol 71 (1999) 235-242
18. Veglio M., Bruno G., Borra M., Macchia G., Bargero G., D'Errico N., et al. Prevalence of increased QT interval duration and dispersion in type 2 diabetic patients and its relationship with coronary heart disease: a population-based cohort. J Intern Med 251 (2002) 317-324
19. Aytemir K., Aksöyek S., Ozer N., Gürlek A., and Oto A. QT dispersion and autonomic nervous system function in patients with type 1 diabetes. Int J Cardiol 65 (1998) 45-50
20. Wei K., Dorian P., Newman D., and Langer A. Association between QT dispersion and autonomic dysfunction in patients with diabetes mellitus. J Am Coll Cardiol 26 (1995) 859-863
21. Veglio M., Giunti S., Stevens L.K., Fuller J.H., Perin P.C., and EURODIAB IDDM Complications Study Group. Prevalence of Q-T interval dispersion in type 1 diabetes and its relation with cardiac ischemia: the EURODIAB IDDM Complications Study Group. Diabetes Care 25 (2002) 702-707
22. Psallas M., Tentolouris N., Papadogiannis D., Doulgerakis D., Kokkinos A., Cokkinos D.V., et al. QT dispersion: comparison between participants with Type 1 and 2 diabetes and association with microalbuminuria in diabetes. J Diabetes Complications 20 (2006) 88-97
23. Earle K.A., Mishra B., Morocutti A., Barnes D., Chambers J., and Viberti G.C. QT dispersion in microalbuminuric Type 1 diabetic patients without myocardial ischemia. J Diabetes Complications 14 (2000) 277-280
24. Weber K.T., Brilla C.G., and Janicki J.S. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 27 (1993) 341-348
25. van Hoeven K.H., and Factor S.M. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 82 (1990) 848-855
26. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
27. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
28. Levantesi G., Scarano M., Marfisi R., Borrelli G., Rutjes A.W., Silletta M.G., et al. Meta-analysis of effect of statin treatment on risk of sudden death. Am J Cardiol 100 (2007) 1644-1650
29. Vyas A.K., et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 47 (2006) 769-773
30. DeSutter J., De Bacquer D., Jordaens L., De Buyzere M., Matthys K., and De Backer G. Heart Rhythm Society 2006 Annual Scientific Sessions. Boston, Massachusetts, May 17-20. Intensive lipid-lowering therapy and ventricular arrhythmias in patients with coronary artery disease and internal cardioverter defibrillators (2006)
31. Goldberger J.J., et al. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 48 (2006) 1228-1233
32. Mark L., and Katona A. Effect of fluvastatin on QT dispersion: a new pleiotropic effect?. Am J Cardiol 85 (2000) 919-920
33. Gualdiero P., Esposito K., Ciotola M., Marfella R., and Giugliano D. Simvastatin normalizes qtc dispersion and reduces ventricular electrical instability in isolated hypercholesterolemia. J Endocrinol Invest 25 (2002) RC16-RC18
34. Lee T.M., Lin M.S., Chou T.F., and Chang N.C. Effect of simvastatin on left ventricular mass in hypercholesterolemic rabbits. Am J Physiol Heart Circ Physiol 288 (2005) H1352-H1358
35. Takemoto M., Node K., Nakagami H., Liao Y., Grimm M., Takemoto Y., et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 108 (2001) 1429-1437
36. Bauersachs J., Galuppo P., Fraccarollo D., Christ M., and Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104 (2001) 982-985
37. Tekin G., Tekin A., Canatar T., Sipahi I., Unsal A., Katircibaşi T., et al. Simvastatin improves the attenuated heart rate recovery of type 2 diabetics. Pharmacol Res 54 (2006) 442-446
38. Riahi S., Christensen J.H., Toft E., Skou H.A., and Schmidt E.B. HMG-CoA reductase inhibitors improve heart rate variability in patients with a previous myocardial infarction. Pharmacol Res 45 (2002) 479-483
39. Pound E.M., Kang J.X., and Leaf A. Partitioning of polyunsaturated fatty acids, which prevent cardiac arrhythmias, into phospholipid cell membranes. J Lipid Res 42 (2001) 346-351